This real‐world study at a single academic center retrospectively examined the drug survival
of apremilast for patients with psoriasis. Retrospective information was extracted from the …

Objectives To investigate the survival of apremilast in a cohort of psoriasis patients treated
with apremilast in a Greek hospital. Methods A retrospective cross-sectional study examined …

Apremilast is the first small molecule approved for the treatment of moderate to severe
psoriasis and psoriatic arthritis in adult patients. To evaluate survival, efficacy and safety of …

There is limited evidence about the real‐world survival of apremilast in patients with
psoriasis, especially over the long term. To evaluate the long‐term survival of apremilast and …

Apremilast is a relatively new therapy for the treatment of moderate to severe plaque
psoriasis in adults. While this medication is considered safe with a very low risk of serious …

Objectives The aim of this paper is to present our personal as well as literature-sourced real-
world evidenced on apremilast use in psoriasis patients with serious baseline comorbidities …

Background: Real-world data differ from clinical trial data. Although some real-world data
regarding apremilast use for psoriasis treatment has been reported in Western countries, no …

Baseline characteristics Female, n (%) 83 (63.3) 92 (54.8) 95 (58.6) 88 (53) 275 (55.3). 11
Mean age, y (SD) 57.5 (12) 51.4 (11.7) 50.5 (11.2) 49.9 (11.4) 50.6 (11.4) Mean duration of …

Purpose: Apremilast, an oral phosphodiesterase 4 inhibitor, was effective in clinical trials in
patients with moderate plaque psoriasis (affected body surface area [BSA] 5% to 10%) …

Background Randomized, controlled trials demonstrated efficacy and safety of apremilast for
moderate-to-severe plaque psoriasis and psoriatic arthritis. Objective Assess long-term …